Orphan Drugs: From Biotech Niche to Pharma Focus
March 10 |
Vol. Volume 2
No. Number 8
Focusing on the rare disease market, we provide an overview of the Orphan Drug Act of 1983 and discuss the nature of orphan drug development and commercialization.We analyze the moats in rare disease markets, and why large pharmaceutical firms are increasingly interested in orphan drugs. Finally, we assess what happens when rare disease markets turn competitive, and we offer some case studies.
Mergers & Acquisitions: Outlook for 2010
February 10 |
Volume 2
Number 7
In our annual analysis of the mergers and acquisitions environment, we focus on our expectations for M&A in the drug industry in 2010. We include our rankings of takeout targets among the 58 biotech and specialty pharmaceutical firms on our coverage list. We also provide our view on M&A trends within large pharmaceuticals,devices, instruments, and services.
The Future Image of the Radiology Industry
January 10 |
Volume 2
Number 6
The market demand for cutting-edge imaging has expanded rapidly over the past several years, and regulatory pressures and new competition—from low-cost alternatives to high-tech entrants—have begun to reshape the industry’s growth trajectory. We provide an overview of the imaging business and an outlook for reimbursement changes. We also highlight the emerging teleradiology industry.
The Year Ahead: Key Drivers in a Post-Reform Environment
December 09 |
Volume 2
Number 5
The passage of U.S. health-care reform could mark a dramatic start to 2010, and we offer our view of the potential ramifications for the various industries within the sector. Beyond reform, we provide our take on the major events and trends we see driving each industry, including a breakdown of the new drugs and devices we think are likely to lead the way in favorable clinical data or commercial launches.
Taking the Pulse of Innovation in Atrial Fibrillation
November 09 |
Volume 2
Number 4
Atrial fibrillation is an extremely difficult-to-treat cardiovascular disease that affects millions, and drug and device companies alike are racing to develop new treatments. In this report we analyze the nature of the disease and current treatment offerings, and we review which companies appear poised to introduce more effective drugs with blockbuster potential.